Lupin Pharma Canada limited, established in Toronto & Montreal in 2014, is the Canadian subsidiary of Lupin Limited, which is the third largest pharmaceutical company in India.
Since its inception in 1968, Lupin Limited, headquartered in Mumbai, India, has expanded its pharmaceutical expertise across the globe in pursuit of its desire to help improve people’s lives.
Building on its parent company’s solid reputation, Lupin Pharma Canada Limited is committed to strengthening its branded product portfolio with the launch of additional medicines developed from its own research and manufacturing process, as well as through strategic brand acquisitions and licensing.
Contact
1001 De Maisonneuve Est, Suite 304, Montreal, Quebec, Canada, H2L 4P9
Tel + 1 844 587-4623
Patrick Nadeau, vice-president (business development, marketing and operations) of Lupin Pharma Canada, highlights the journey of Lupin Pharma within Canada since its 2014 establishment, the strategic importance of the Canadian…
A roundup of some of the top stories from the Indian pharma industry including the suspension of the National Medical Commission’s (NMC) guidelines making the prescription of generic drugs mandatory;…
Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can…
Ricardo Lourenço, VP-Managing Director of Lupin in Brazil has been in charge of implementing the take over of Medquímica by Lupin. In this interview he explains Brazil is a land…
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the leading country in its region. Despite the prevalence…
Patrick Nadeau, vice-president (business development, marketing and operations) of Lupin Pharma Canada, highlights the journey of Lupin Pharma within Canada since its 2014 establishment, the strategic importance of the Canadian…
Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s…
Lupin’s EMEA President Thierry Volle explains that to fuel growth in the EMEA region, Lupin is investing heavily in transforming the business from a generics company into a specialty pharma…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Two weeks ago, Lupin announced its annual results, portraying 6 years of sustained growth and a net profit up by 27%. How pleased were you with this performance, and were…
See our Cookie Privacy Policy Here
